• Sawant M, Mahajan K, Renganathan A, Weimholt C, Luo J, Kukshal V, Jez JM, Jeon MS, Zhang B, Li T, Fang B, Lawrence NJ, Luo Y,  Lawrence HR, Feng FY, and Mahajan NP*. Modified androgen receptor in recurrent castration resistant prostate cancer and its therapeutic targeting. Science Translational Medicine, 2022. https://www.science.org/doi/10.1126/scitranslmed.abg4132
  • Chouhan S, Sawant M, Weimholt C, Luo J, Sprung RW, Terrado M, Mueller DM, Earp HS and Mahajan NP*. ACK1/TNK2 Mediated Phosphorylation of ATP Synthase α-Subunit Selectively Augments Survival of Prostate Cancer While Engendering Mitochondrial Vulnerability. Autophagy , 2022.
  • Ghildiyal R., Sawant M, Renganathan A, Kim E, Luo J, Mahajan K, Feng F and Mahajan NP*. Loss of long non-coding RNA NXTAR in prostate cancer augments androgen receptor expression and enzalutamide resistance. Cancer Research, 82(1):155-168, 2022. Pubmed ID: 34740892
Altmetric: 99th percentile
  • Nguyen DT, Yang W, Renganathan A, Weimholt C, Angappulige D, Nguyen T, Sprung RW, Andriole GL, Kim EH, Mahajan NP, and Kiran Mahajan. Acetylated HOXB13 Regulated Super Enhancer Genes Define Therapeutic Vulnerabilities of Castration-Resistant Prostate Cancer. Clinical Cancer Research, 2022. Pubmed ID:
  • Tahir R, Madugundu A, Udainiya S, Cutler J, Renuse S, Wang L, Pearson N, Mitchell C, Mahajan NP, Pandey A, Wu X. Proximity-dependent biotinylation to elucidate the interactome of TNK2 non-receptor tyrosine kinase. Journal of Proteome Research, 20(9):4566-4577, 2021. Pubmed ID: 34428048
  • Zhao S, Chen W, Li H, Foye A, Zhang M, Sjöström M, Aggarwal R, Playdle D, Liao A, Alumkal J, Das R, Chi K, Gleave M, Zoubeidi A, Reiter R, Rettig M, Witte O, Kim MY, Fong L,  Spratt D, Morgan T, Bose R, Huang F, Li H, Chesner L, Shenoy T, Goodarzi H, Asangani I, Sandhu S, Lang J, Mahajan NP, Lara P, Evans CP, Tomlins S, Wyatt A, Dehm S, Ashworth A, Gilbert L, Boutros P, Farh K, Maher C, Small E*, Quigley D*, Chinnaiyan A*, Feng F*. DNA methylation landscapes in advanced prostate cancer. Nature Genetics, 52(8):778-789, 2020. Pubmed ID: 32661416
  • Gu J, Qian L, Zhang G, Mahajan NP, Owonikoko T, Ramalingam SR, Sun SY. Inhibition of ACK1 delays and overcomes acquired resistance of EGFR mutant NSCLC cells to the third generation EGFR inhibitor, osimertinib. Lung Cancer, 150:26-35. 2020. Pubmed ID: 33049499
  • Kim EH, Cao D, Mahajan NP, Andriole GL and Mahajan K. ACK1-AR and AR-HOXB13 Signaling Axis: Epigenetic Regulation of Lethal Prostate Cancers. Nucleic Acids Research Cancer, 2(3):zcaa018, 2020. Pubmed ID: 32885168
  • Bossan A, Ottman R, Andl T, Hasan MF, Mahajan N, Coppola D and Chakrabarti R. Expression of FGD4 positively correlates with the aggressive phenotype of prostate cancer. BMC Cancer, 18:1257, 2018. Pubmed ID: 30558664
  • Mahajan K, Malla P, Lawrence H, Chen Z, Sinha CK, Malik R, Shukla S, Kim J, Coppola D, Lawrence N and Mahajan NP*. ACK1 regulates histone Tyr-phosphorylation and AR gene expression in castration resistant prostate cancer. Cancer Cell 2017. Pubmed ID: 28609657
    • Highlighted by scores of internet websites
    • New class of small molecule inhibitor for prostate cancer
  • Mahajan NP*, Malla P, Bhagwat S, Sarnaik A, Kim J, Pilon-Thomas S, Weber J and Mahajan K*. WEE1 epigenetically modulates 5-hmC levels by pY37-H2B dependent regulation of IDH2 gene expression. Oncotarget 2017. Pubmed ID:29290954
  • Mahajan NP*, Coppola D, Kim J, Lawrence H, Lawrence NJ and Mahajan K*. Blockade of ACK1/TNK2 to squelch the survival of prostate cancer stem-like cells. Scientific Reports 2018. Pubmed ID:29386546
  • Wu X, Zahari MS, Renuse S, Bharbuiya MA, Rojas PL, Kelkar DS, Sterns V, Gabrielson E, Sukumar S, Malla P, Mahajan NP*, Pandey A*. The non-receptor Tyrosine kinase TNK2/ACK1 is a novel therapeutic target in triple negative breast cancer. Oncotarget 2017. PubMed ID: 27902967
  • Mahajan K and Mahajan NP*. Cross talk of Tyrosine Kinases with the DNA Damage Signaling Pathways. Nucleic Acids Research 2015. Pubmed ID:26546517 
  • Paranjape A, Soundararajan R, Werden S, Joseph R, Taube J, Liu H, Rodriguez-Canales J, Sphyris N, Wistuba I, Dhillon J, Mahajan N, Mahajan K, Chang J, Ittmann M, Maity S, Logothetis C, Miura N, Tang D, Mani S. Inhibition of FOXC2 restores epithelial phenotype and drug-sensitivity in prostate cancer cells with stem-like properties. Oncogene 2016. Pubmed ID: 26804168
  • Lawrence HR, Mahajan K, Liu Y, Zhang D, Tindal N, Huseyin M, Gevariya H, Kazi S, Ozcan S, Mahajan NP* and Lawrence NJ*. Development of novel ACK1 inhibitors using a fragment based approach. J Med Chem 2015. Pubmed ID:25699576
  • Mahajan K and Mahajan NP*. ACK1/TNK2 Tyrosine Kinase: Molecular Signaling and Evolving Role in Cancers. Oncogene 2015. Pubmed ID: 25347744 
  • Mahajan K, Lawrence H, Lawrence NJ and Mahajan NP*. ACK1 Tyrosine Kinase Interacts with Histone Demethylase KDM3A to Regulate the Mammary Tumor Oncogene HOXA1 . Journal of Biological Chemistry 2014. Pubmed ID: 25148682 
  • Mahajan K and Mahajan NP*. AKT goes cycling. Cancer Control 2014. Pubmed ID: 24955708
  • Mahajan K and Mahajan NP*. WEE1 tyrosine kinase, a novel epigenetic modifier. Trends in Genetics 2013. Pubmed ID: 23537585
  • Linderoth E, Pilia G, Mahajan NP, Ferby I. Activated Cdc42-associated Kinase 1 (Ack1) Is Required for Tumor Necrosis Factor-related Apoptosis-inducing Ligand (TRAIL) Receptor Recruitment to Lipid Rafts and Induction of Cell Death. Journal of Biological Chemistry 2013. Pubmed ID: 24085293
  • Mahajan K and Mahajan NP*. ACK1 tyrosine kinase: targeted inhibition to block cancer cell proliferation. Cancer Letters 2013. Pubmed ID: 23597703
  • Buchwald M, Pietschmann K, Brand P, Gunther A, Mahajan NP, Heinzel T and Kramer OH. SIAH ubiquitin ligases target the nonreceptor tyrosine kinase ACK1 for ubiquitinylation and proteosomal degradation. Oncogene 2013. Pubmed ID:23208506
  • Mahajan K, Fang B, Koomen JM and Mahajan NP*. H2B Tyr37 phosphorylation suppresses expression of replication-dependent core histone genes. Nature Structural & Molecular biology 2012. Pubmed ID: 22885324
    • Article of the month
    • Highlighted by Nature on their website 
  • Mahajan K, Coppola D, Rawal B, Chen YA, Lawrence H, Engelman RW, Lawrence NJ and Mahajan NP*. Ack1 mediated androgen receptor phosphorylation modulates radiation resistance in castration resistant prostate cancer. Journal of Biological Chemistry 2012. Pubmed ID: 22566699 
  • Mahajan K and Mahajan NP*. PI3K-independent AKT activation: A Treasure Trove of Novel Therapeutics. Journal of Cellular Physiology 2012. Pubmed ID:22307544 
  • Mahajan K, Coppola D, Lawrence H, Luo Y, Zhu W, Chen AJ, Lawrence NJ,Mahajan NP*. Ack1 correlates with pancreatic cancer progression. American Journal of Pathology 2012. Pubmed ID: 22322295  
  • Lin HY, Park HY, Radlein S, Mahajan NP, Sellers TS, Zachariah B, Pow-Sang J, Coppola D, Ganapathy V, Park JY. SLC5A8 gene variation and protein levels in prostate cancer risk and aggressiveness. Urology 2011. Pubmed ID: 20623637  
  • Mahajan K, Challa S, Coppola D, Lawrence H, Luo Y, Zhu W, Chen A, Lawrence NJ and Mahajan NP*. Effect of Ack1 Tyrosine Kinase Inhibitor on Ligand-Independent Androgen Receptor Activity. Prostate 2010. Pubmed ID: 20623637  
  • Mahajan K and Mahajan NP*. Shepherding Androgen receptor and AKT by Ack1 in hormonally regulated cancers. Journal of Cellular Physiology 224:327-33, 2010. Pubmed ID: 20333297 
  • Mahajan K, Coppola D, Challa S, Fang B, Chen YA, Zhu W, Lopez AS, Koomen J, Engelman RW, Rivera C, Muraoka-Cook RS, Cheng JQ, Schonbrunn E, Sebti SM, Earp HS, Mahajan NP*. Ack1 Mediated AKT/PKB Tyrosine 176 Phosphorylation Regulates Its Activation. PLoS One 5:e9646, 2010. Pubmed ID: 20333297 
  • Mahajan NP, Liu Y, Majumder S, Warren MR, Parker CE, Mohler JL, Earp HS, Whang YE. Activated Cdc42-associated kinase Ack1 promotes prostate cancer progression via androgen receptor tyrosine phosphorylation. Proc Natl Acad Sci USA 104:8438-8443, 2007. Pubmed ID: 17494760 
  • Mahajan NP, Whang YE, Mohler JL, Earp HS. Activated tyrosine kinase Ack1 promotes prostate tumorigenesis: role of Ack1 in polyubiquitination of tumor suppressor Wwox. Cancer Research 65:10514-10523, 2005. Pubmed ID:16288044 
  • Li Y, Mahajan NP, Webster-Cyriaque J, Bhende P, Hong GK, Earp HS, Kenney S. The C-mer gene is induced by Epstein-Barr virus immediate-early protein BRLF1. Journal of Virology 78:11778-11785, 2004. Pubmed ID: 15479819 
  • Mahajan NP, Earp HS. An SH2 domain-dependent, phosphotyrosine-independent interaction between Vav1 and the Mer receptor tyrosine kinase: a mechanism for localizing guanine nucleotide-exchange factor action. J Biol Chem. 278:42596-42603, 2003. Pubmed ID: 12920122 
  • Guttridge KL, Luft JC, Dawson TL, Kozlowska E, Mahajan NP, Varnum B, Earp HS. Mer receptor tyrosine kinase signaling: prevention of apoptosis and alteration of cytoskeletal architecture without stimulation or proliferation. J Biol Chem.277:24057-24066, 2002. Pubmed ID: 11929866 
  • Mahajan K, Gangi-Peterson L, Sorscher D, Wang J, Gathy K, Mahajan NP, Reeves W, Mitchell B. Association of terminal deoxynucleotidyl transferase with Ku.Proc Natl Acad Sci USA. 96:13926-13931, 1999. Pubmed ID: 10570175 
  • Mahajan NP, Harrison-Shostak D, Michaux J, Herman B. Novel mutant green fluorescent protein protease substrates reveal the activation of specific caspases during apoptosis. Chemistry & Biology 6:401-409, 1999. Pubmed ID:10375546
  • Mahajan NP, Linder K, Berry G, Gordon G, Heim R, Herman B. Bcl-2 and Bax interactions in mitochondria probed with green fluorescent protein and fluorescence resonance energy transfer. Nature Biotechnology 16:547-552, 1998. Pubmed ID: 9624685
    • Reviewed by Chemistry & Biology, Vol 5, R317-R322 (1998)
    •  Highlighted in the same issue of  Nature Biotechnology 
  • Mahajan NP, Rao C. Nucleotide sequence and expression in E. coli of the complete P4 type VP4 from a G2 serotype human rotavirus. Arch Virol. 141:315-329, 1996. Pubmed ID: 86340233 
  • Zha H, Fisk H, Yaffe M, Mahajan N, Herman B, Reed J. Structure-function comparisons of proapoptotic protein Bax in yeast and mammalian cells. Mol Cell Biol. 16:6494-08, 1996, Pubmed ID: 8887678

BOOK CHAPTERS

  • Mahajan K, Mahajan N. ACK1/TNK2 tyrosine kinase:An emerging target for cancer therapeutics In: AACR Yearbook, 2014 
  • Herman, B, Wang, X, Wodnicki, P, Perisamy A, Mahajan N, Berry G and Gordon G. Fluorescence Lifetime Imaging Microscopy. Applied Fluorescence in Chemistry, Biology and Medicine In: W. Rettig, B. Strehmel, S. Schrader and H. Seifert (Eds.), Springer Verlag Press, Berlin Heidelberg, 1998. 
  • Herman B, Mahajan N, Casanova E, Michaux J and Gordon G. Two fusion FRET: A new means to observe structural and functional protein dynamics in living cells. 3rd conference on fluorescence microscopy and fluorescent probes, 2000. 
  • Herman B, Gordon G, Mahajan N and Centonze V. Measurement of fluorescence resonance energy transfer in the optical microscope. Methods in Cellular Imaging In: Periasamy A (Ed.), Oxford University Press, New York, New York, 2001.

PATENTS

  1.      Title: Inhibitors of ACK1/TNK2 Tyrosine Kinase
         US Patent No. 9,850,216
  2.      Title: AKT Tyrosine 176 Phosphorylation as Cancer Biomarker
         US Patent No. 8,557,516
  3.     Title: Phosphorylated histones and uses thereof
        U.S. Patent No. 9,594,084
  4.     Title: Inhibitors of ACK1/TNK2 Tyrosine Kinase
        US Patent No. 10,017,
    478
  5.     Title: Allosteric inhibitor of WEE1 kinase
        Serial # 19/44922 
  6.     Title: Methods for Diagnosis and Prognosis of Epithelial Tumors
        Serial #
    15/525,787
  7.     Title: Methods for treatment of disorders related to phosphorylation of histones
        Serial # 14/860,405
  8.     Title: ACK1 kinase inhibition to treat triple negative breast cancer
        Serial # 13/965,034